Kraig Biocraft Laboratories Inc (KBLB)

[golferman]

This statement is wrong as per the S-1A

That is correct. The possibility of selling at least 110M shares was calculated using the .04 level.

The 7.5 M line of equity was based on a average stock price of .0853. so expect news to come to move the price.

A quote from the S-1A page 12

We may not have access to the full amount under the Equity Line.

As of May 14, 2015, the closing market price of our common stock was $0.048. There is no assurance that the market price of our Class A common stock will increase substantially in the near future. The entire commitment under the Equity Line Financing is $7,500,000 as of the date of this prospectus. We would need to maintain the market price of our Class A common stock at approximately $0.0853 in order to have access to the full amount under the Equity Line Financing. Since January 1, 2012, the lowest and the highest prices at which our Class A common stock has been trading were $0.021 and $0.136 per share, respectively. We expect that, initially, the resale by Calm Seas Capital of the shares of our Class A common stock that we will sell to them under our Equity Line Financing will cause our stock to decrease. However, if we are able to report positive developments in our research and development efforts, we expect that such announcements will cause our stock price to increase sufficiently to a price per share above the price we need to allow us to obtain $7,500,000 gross proceeds under the Equity Line Financing. If we achieve our research and development goals, we expect that the announcement of such achievements will have a significant positive impact on the price of our Class A common stock. Technology research and development is very risky. We cannot be certain that we will achieve our research and development goals. Any setbacks in our research and development activities may cause our stock price to drop, in which event we would probably not be able to raise $7,500,000 under our Equity Line Financing. In the event that we raise substantially less than the maximum proceeds we expect to raise under the Equity Line Financing by the expiration of their respective terms, we will seek to raise funds from other capital sources. Alternatively, if our research yields some promising or positive results, we may seek a corporate partner in a joint venture or licensing arrangement in which we would seek to negotiation an upfront licensing fee and/or capital investment from such corporate partner. We have not yet identified any corporate partners for any such joint venture or licensing arrangement.